JP6284928B2 - ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス - Google Patents

ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス Download PDF

Info

Publication number
JP6284928B2
JP6284928B2 JP2015512900A JP2015512900A JP6284928B2 JP 6284928 B2 JP6284928 B2 JP 6284928B2 JP 2015512900 A JP2015512900 A JP 2015512900A JP 2015512900 A JP2015512900 A JP 2015512900A JP 6284928 B2 JP6284928 B2 JP 6284928B2
Authority
JP
Japan
Prior art keywords
substituted
compound
unsubstituted
salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015512900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517532A5 (enExample
JP2015517532A (ja
Inventor
デイビッド アスキン,
デイビッド アスキン,
チョン ハン,
チョン ハン,
ジョナサン ダブリュー. レーン,
ジョナサン ダブリュー. レーン,
トラヴィス リマルチュック,
トラヴィス リマルチュック,
セイガー シャーキャ,
セイガー シャーキャ,
シー. グレゴリー ソーウェル,
シー. グレゴリー ソーウェル,
ケイス エル. スペンサー,
ケイス エル. スペンサー,
ピーター ジェイ. ステンゲル,
ピーター ジェイ. ステンゲル,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2015517532A publication Critical patent/JP2015517532A/ja
Publication of JP2015517532A5 publication Critical patent/JP2015517532A5/ja
Application granted granted Critical
Publication of JP6284928B2 publication Critical patent/JP6284928B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
JP2015512900A 2012-05-17 2013-05-17 ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス Active JP6284928B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261648473P 2012-05-17 2012-05-17
US61/648,473 2012-05-17
US201361785122P 2013-03-14 2013-03-14
US61/785,122 2013-03-14
PCT/US2013/041666 WO2013173768A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Publications (3)

Publication Number Publication Date
JP2015517532A JP2015517532A (ja) 2015-06-22
JP2015517532A5 JP2015517532A5 (enExample) 2016-06-30
JP6284928B2 true JP6284928B2 (ja) 2018-02-28

Family

ID=48485537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512900A Active JP6284928B2 (ja) 2012-05-17 2013-05-17 ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス

Country Status (20)

Country Link
US (4) US9416110B2 (enExample)
EP (1) EP2861582B1 (enExample)
JP (1) JP6284928B2 (enExample)
KR (1) KR102067850B1 (enExample)
CN (1) CN104470913B (enExample)
AU (1) AU2013262505B2 (enExample)
BR (1) BR112014028589B1 (enExample)
CA (1) CA2873654C (enExample)
DK (1) DK2861582T3 (enExample)
ES (1) ES2582557T3 (enExample)
IL (1) IL235715A (enExample)
MX (1) MX353384B (enExample)
MY (1) MY169028A (enExample)
NZ (1) NZ702935A (enExample)
PL (1) PL2861582T3 (enExample)
RU (1) RU2643811C2 (enExample)
SG (1) SG11201407616TA (enExample)
SI (1) SI2861582T1 (enExample)
WO (1) WO2013173768A1 (enExample)
ZA (1) ZA201409261B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173736A1 (en) 2012-05-17 2013-11-21 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
PE20150725A1 (es) 2012-05-17 2015-05-17 Genentech Inc Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este
NZ702950A (en) 2012-05-17 2016-09-30 Genentech Inc Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
CA2873654C (en) 2012-05-17 2021-06-22 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
ES2957314T3 (es) 2013-11-15 2024-01-17 Hoffmann La Roche Procesos para la preparación de compuestos de pirimidinilciclopentano
SG11201702324QA (en) * 2014-09-26 2017-04-27 Hoffmann La Roche PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS
CN109789141B (zh) 2016-08-10 2022-08-26 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
MX2022015322A (es) 2020-06-16 2023-01-11 Hoffmann La Roche Proceso para elaborar compuestos de ciclopentilpirimidina hidroxilada.
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1134212C (zh) 1993-12-12 2004-01-14 阿格罗吉恩有限公司 保护植物免受真菌侵染的新方法
AU724216B2 (en) 1997-04-07 2000-09-14 Merck & Co., Inc. A method of treating cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
US6376496B1 (en) 1999-03-03 2002-04-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CN1281604C (zh) * 1999-06-03 2006-10-25 帝国脏器制药株式会社 取代吡唑化合物
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
WO2004108673A2 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
CA2758484A1 (en) 2009-04-15 2010-10-21 David A. Degoey Anti-viral compounds
JP5581390B2 (ja) * 2009-10-23 2014-08-27 イーライ リリー アンド カンパニー Akt阻害剤
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
PE20150725A1 (es) 2012-05-17 2015-05-17 Genentech Inc Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este
CA2873658C (en) 2012-05-17 2021-01-26 Genentech, Inc. Process for making amino acid compounds
CA2873654C (en) 2012-05-17 2021-06-22 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
WO2013173736A1 (en) 2012-05-17 2013-11-21 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
NZ702950A (en) 2012-05-17 2016-09-30 Genentech Inc Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
US20140121193A1 (en) 2012-11-01 2014-05-01 Robert S. Katz Methods for treating fibromyalgia
EP2956441A4 (en) 2013-02-18 2016-11-02 Scripps Research Inst MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
US10131637B2 (en) 2013-03-15 2018-11-20 Shifa Biomedical Corporation Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Also Published As

Publication number Publication date
KR102067850B1 (ko) 2020-01-17
US9676730B2 (en) 2017-06-13
ES2582557T3 (es) 2016-09-13
US20180258054A1 (en) 2018-09-13
EP2861582B1 (en) 2016-05-25
US20170247337A1 (en) 2017-08-31
US20160318877A1 (en) 2016-11-03
DK2861582T3 (en) 2016-08-22
EP2861582A1 (en) 2015-04-22
US9790190B2 (en) 2017-10-17
ZA201409261B (en) 2017-05-31
MX353384B (es) 2018-01-10
BR112014028589B1 (pt) 2022-08-23
KR20150020214A (ko) 2015-02-25
BR112014028589A2 (pt) 2017-07-25
SI2861582T1 (sl) 2016-09-30
NZ702935A (en) 2017-02-24
US20150152067A1 (en) 2015-06-04
SG11201407616TA (en) 2015-03-30
PL2861582T3 (pl) 2016-11-30
WO2013173768A1 (en) 2013-11-21
MX2014013862A (es) 2015-05-07
CA2873654C (en) 2021-06-22
RU2643811C2 (ru) 2018-02-06
HK1208451A1 (en) 2016-03-04
AU2013262505A1 (en) 2015-01-22
AU2013262505B2 (en) 2017-09-21
IL235715A (en) 2017-02-28
IL235715A0 (en) 2015-02-01
US9416110B2 (en) 2016-08-16
CN104470913B (zh) 2018-07-20
CN104470913A (zh) 2015-03-25
JP2015517532A (ja) 2015-06-22
MY169028A (en) 2019-02-04
RU2014151050A (ru) 2016-07-10
CA2873654A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
JP6284928B2 (ja) ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
JP6196294B2 (ja) アミノ酸化合物を製造するためのプロセス
US10870626B2 (en) Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK1208451B (zh) 用於製造羥基化的環戊基嘧啶化合物的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180131

R150 Certificate of patent or registration of utility model

Ref document number: 6284928

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250